Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

Richard D. Olson, Phillip S. Mushlin · The FASEB Journal · 1990 · 687 citations

Medicine, Pharmacology, Toxicology +16

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

Yasuhiro Matsumura, Tsuyoshi Hamaguchi, Takashi Ura et al. · British Journal of Cancer · 2004 · 617 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

Maaike de Boer, Carolien H. M. van Deurzen, J.A.A.M. van Dijck et al. · New England Journal of Medicine · 2009 · 536 citations · Full text

Medicine, Oncology, Pathology +17

Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.

Armando Bartolazzi, R Peach, Alejandro Aruffo et al. · The Journal of Experimental Medicine · 1994 · 341 citations · Full text

Medicine, Molecular Biology, Oncology +15